Hapten Sciences Overview

  • Year Founded
  • 2010

Year Founded

  • Status
  • Private

  • Latest Deal Type
  • Later Stage VC

  • Latest Deal Amount
  • $6.92M

  • Investors
  • 2

Hapten Sciences General Information

Description

Developer of novel molecular drugs intended to significantly contribute to the health and well-being of people worldwide. The company's drugs act as a vaccine to prevent contact dermatitis caused by exposure to urushiol oil in poison ivy, poison oak, or poison sumac, enabling patients to avoid an allergic reaction without any side effects.

Contact Information

Website
www.haptensciences.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 700 Colonial Road
  • Suite 105
  • Memphis, TN 38117
  • United States
+1 (901)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Life Sciences
Corporate Office
  • 700 Colonial Road
  • Suite 105
  • Memphis, TN 38117
  • United States
+1 (901)

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Hapten Sciences Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Later Stage VC 31-Oct-2019 $6.92M Completed Clinical Trials - Phase 1
4. Later Stage VC (Series 1) 04-Feb-2015 Completed Clinical Trials - Phase 1
3. Early Stage VC (Series 1) 01-Jun-2013 Completed Clinical Trials - Phase 1
2. Early Stage VC (Series 1) 01-Jun-2012 $700K $700K Completed Clinical Trials - Phase 1
1. Grant $800K Completed Startup
To view Hapten Sciences’s complete valuation and funding history, request access »

Hapten Sciences Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Series 1
To view Hapten Sciences’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Request a free trial

Hapten Sciences Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of novel molecular drugs intended to significantly contribute to the health and well-being of people worldwide
Drug Discovery
Memphis, TN

Bangalore, India
 

Manchester, United Kingdom
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Hapten Sciences Competitors (22)

One of Hapten Sciences’s 22 competitors is GangaGen, a Venture Capital-Backed company based in Bangalore, India.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
GangaGen Venture Capital-Backed Bangalore, India
F2G Venture Capital-Backed Manchester, United Kingdom
Iconic Therapeutics Formerly VC-backed South San Francisco, CA
Mesoblast Corporation Melbourne, Australia
Bionomics Formerly VC-backed Sydney, Australia
You’re viewing 5 of 22 competitors. Get the full list »

Hapten Sciences Patents

  • 4

    Total Documents Applications and Grants

  • Total Patents Families

  • 2

    Granted

  • 1

    Pending

  • Expiring in next 12 mo

Hapten Sciences Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
CA-3091168-A1 Patches comprising urushiol, test panels comprising the same, and methods of using the same Pending 13-Feb-2018
US-20200405886-A1 Patches comprising urushiol, test panels comprising the same, and methods of using the same Active 13-Feb-2018
US-11666667-B2 Patches comprising urushiol, test panels comprising the same, and methods of using the same Active 13-Feb-2018
US-20240100195-A1 Patches comprising urushiol, test panels comprising the same, and methods of using the same Inactive 13-Feb-2018 A61K49/0006

Hapten Sciences Investors (2)

Investor Name Investor Type Holding Investor Since Participating Rounds
MB Venture Partners Venture Capital Minority
National Institutes of Health Government
To view Hapten Sciences’s complete investors history, request access »

Ready to get started?

Request a free trial

Hapten Sciences FAQs

  • When was Hapten Sciences founded?

    Hapten Sciences was founded in 2010.

  • Where is Hapten Sciences headquartered?

    Hapten Sciences is headquartered in Memphis, TN.

  • What industry is Hapten Sciences in?

    Hapten Sciences’s primary industry is Drug Discovery.

  • Is Hapten Sciences a private or public company?

    Hapten Sciences is a Private company.

  • What is Hapten Sciences’s current revenue?

    The current revenue for Hapten Sciences is .

  • How much funding has Hapten Sciences raised over time?

    Hapten Sciences has raised $8.57M.

  • Who are Hapten Sciences’s investors?

    MB Venture Partners and National Institutes of Health have invested in Hapten Sciences.

  • Who are Hapten Sciences’s competitors?

    GangaGen, F2G, Iconic Therapeutics, Mesoblast, and Bionomics are some of the 22 competitors of Hapten Sciences.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »